Invex Therapeutics Ltd. (IXC) AI Stock Analysis

• Market Cap: AU$7.89M
• Dividend Yield: N/A
• Average Volume (3M): 49.57K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.58
• Revenue Growth: N/A
• EPS Growth: 71.10%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 75,153,850
• 10 Day Avg. Volume: 15,093
• 30 Day Avg. Volume: 49,574
• PEG Ratio: 0.20
• Price to Book (P/B): 1.28
• Price to Sales (P/S): 29.41
• P/FCF Ratio: -10.32
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: AU$0.10 ▼(-13.33% Downside)
• Action: Reiterated Date: 01/21/26
• Date: Action: Reiterated 01/21/26

The score is primarily held back by weak financial performance (volatile and sharply lower revenue, ongoing losses, and persistent cash burn), with some support from a debt-free balance sheet and improving loss/cash outflow trends. Technicals are neutral overall, while valuation remains unattractive due to negative earnings and no dividend yield data.

Positive Factors

Debt-free balance sheet

A debt-free capital structure materially reduces short-to-medium term bankruptcy and refinancing risk for a clinical-stage biotech. This gives management flexibility to fund trials or seek partnerships without mandatory interest burden, supporting operating runway decisions over the next 2–6 months.

Improving cash outflow trends

Progress toward lower cash burn indicates management is beginning to slow negative cash generation, which can extend runway and reduce reliance on dilutive financing. If sustained, improving outflows improve probability of completing clinical milestones or attracting partners over the medium term.

Focused clinical-stage strategy

A concentrated R&D focus on a defined indication (IIH) gives clarity to resource allocation and trial design, aiding efficient progress through regulatory pathways. Specialized therapeutic focus can enhance appeal to strategic partners and align long-term value creation with clinical readouts.

Negative Factors

Steep revenue decline

An ~81% YoY revenue collapse signals weak or non-recurring commercial receipts, leaving the company dependent on financing or milestones. For a development-stage biotech this heightens funding risk and makes multi-period planning and continuity of trials vulnerable absent durable alternative cash sources.

Persistent negative cash generation

Sustained negative operating and free cash flow means the business cannot self-fund development activities and will need external capital or partnerships. Recurrent cash burn increases dilution risk and may force trade-offs in trial progress or R&D scope over the coming months if financing terms are unfavorable.

Eroding equity and negative ROE

Declining equity and persistent negative ROE reflect accumulated losses that dilute shareholder value and constrain balance sheet flexibility. Continued erosion reduces the firm's capacity to absorb additional setbacks or fund trials organically, increasing strategic dependence on external funding or partnerships.

Invex Therapeutics Ltd. Business Overview & Revenue Model

Company Description

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial. The company was incorporated in 2019 and is based in Perth, Australia.

How the Company Makes Money

null

Invex Therapeutics Ltd. Financial Statement Overview

Summary

Financials reflect an early-stage biotech profile: steeply volatile and shrinking revenue (2025 down ~81% YoY), ongoing operating/net losses, and consistently negative operating/free cash flow. Offsetting this, losses and cash outflow improved versus 2024 and the company is debt-free with a meaningful (though declining) equity base.

Income Statement

Revenue is small and highly volatile, with a steep decline in the latest year (2025 revenue down ~81% vs. 2024). Profitability remains weak with persistent operating losses and net losses across all periods shown, although losses have narrowed materially versus 2022–2023. Gross profit is positive when revenue exists, but overall margins remain deeply negative, indicating the business is still far from self-funding.

Balance Sheet

The balance sheet is conservatively positioned with zero debt and a meaningful equity base, which reduces financial risk. However, equity has trended down significantly from 2022–2023 levels, consistent with ongoing losses and cash burn. Returns on equity are negative each year, reflecting continued value dilution risk if losses persist.

Cash Flow

Operating cash flow and free cash flow are negative in every year shown, signaling consistent cash burn. The latest year shows a sizable improvement in cash outflow versus 2024, but cash generation is still not sustainable without external funding. Cash flow performance remains closely tied to losses, and the business has not demonstrated durable positive operating cash generation.

Breakdown	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	229.08K	1.21M	459.08K	182.25K	0.00
Gross Profit	229.08K	1.21M	459.08K	182.25K	0.00
EBITDA	0.00	-720.00K	-8.21M	-4.14M	-2.28M
Net Income	-476.87K	-1.64M	-7.75M	-3.95M	-2.28M
Balance Sheet
Total Assets	5.47M	6.12M	22.80M	29.49M	32.74M
Cash, Cash Equivalents and Short-Term Investments	5.38M	6.03M	22.47M	29.34M	32.72M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	220.59K	431.63K	1.57M	1.00M	658.61K
Stockholders Equity	5.25M	5.69M	21.23M	28.48M	32.08M
Cash Flow
Free Cash Flow	-652.57K	-2.44M	-6.87M	-3.38M	-1.68M
Operating Cash Flow	-652.57K	-2.44M	-6.87M	-3.38M	-1.68M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	0.00	-14.00M	0.00	0.00	8.09M

Invex Therapeutics Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.12
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IXC, the sentiment is Negative. The current price of 0.12 is above the 20-day moving average (MA) of 0.12, above the 50-day MA of 0.12, and above the 200-day MA of 0.11, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 19.99 is Positive, neither overbought nor oversold. The STOCH value of -8.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IXC.

Invex Therapeutics Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IXC	48 Neutral	AU$7.89M	-3.15	-8.72%	―	―	71.10%
CHM	45 Neutral	AU$8.84M	-0.15	2844.96%	―	―	46.28%
ATH	41 Neutral	AU$87.00M	-2.12	-42.68%	―	―	63.46%
RCE	41 Neutral	AU$137.36M	-2.84	―	―	―	0.66%
ADO	40 Underperform	AU$35.68M	-10.60	-142.30%	―	110.44%	35.90%
1AD	37 Underperform	AU$10.20M	-0.48	1068.18%	―	―	31.87%

Invex Therapeutics Ltd. Corporate Events

Invex Reports Promising Exenatide Data in Alzheimer’s ADBrain™ Model

Invex Therapeutics reported new data from its research collaboration with Tessara Therapeutics, showing that exenatide demonstrated multiple potentially beneficial effects in Tessara’s ADBrain™ model of Alzheimer’s disease. In the latest analysis, exenatide reduced neurofilament light chain levels by about 40%, lowered pro‑inflammatory cytokines IL-6 and IL-8, and improved measures of neural network complexity such as branching and branch length, while not significantly affecting phosphorylated tau or insulin‑dependent glucose uptake under the tested conditions; the company views these findings as supportive of exenatide’s potential therapeutic benefit early in Alzheimer’s disease and intends to investigate the observed effects on amyloid‑beta burden further.

The most recent analyst rating on (AU:IXC) stock is a Sell with a A$0.11 price target. To see the full list of analyst forecasts on Invex Therapeutics Ltd. stock, see the AU:IXC Stock Forecast page.

Invex Therapeutics Sets Date and Details for 2025 Annual General Meeting

Invex Therapeutics has announced that its 2025 Annual General Meeting will be held in person at Pathways Corporate in Perth on 17 February 2026 at 3:00pm AWST, with the Notice of Meeting and Explanatory Memorandum made available online via the company’s website and the ASX platform. Shareholders are encouraged to lodge their votes by proxy through Automic’s online portal using their securityholder details, and can obtain meeting materials or raise queries electronically, underscoring the company’s continued use of digital channels for governance communications and shareholder engagement.

The most recent analyst rating on (AU:IXC) stock is a Hold with a A$0.12 price target. To see the full list of analyst forecasts on Invex Therapeutics Ltd. stock, see the AU:IXC Stock Forecast page.